Close mobile menu×
Close mobile menu

Mark G. Frattini, MD, PhD

Board Certifications: 
Medical Oncology
Expertise in: 
Leukemia, Cancer Care
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-5098

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

Board Certifications

  • Medical Oncology

Clinical Expertise

  • Leukemia
  • Cancer Care
  • Acute Leukemia
  • Acute Lymphocytic Leukemia
  • Acute Myelogenous Leukemia
  • Aplastic Anemia
  • Chronic Leukemia
  • Chronic Lymphocytic Leukemia
  • Chronic Myelogenous Leukemia
  • Essential Thrombocythemia
  • Hairy Cell Leukemia
  • Hematologic Malignancy
  • Hemolytic Anemia
  • Immune Thombocytopenic Purpura
  • Large Granular Lymphocytic Leukemia
  • Lymphoblastic Leukemia
  • Myelodysplastic Syndrome
  • Myelofibrosis
  • Myeloproliferative Disorder
  • Polycythemia Vera
  • Waldenstrom's Macroglobulinemia

Specialties

Education & Training

  • MD, University of Chicago - Pritzker School of Medicine
  • 1997 University of Chicago Pritzker School of Medicine
  • Internship: 1998 Johns Hopkins Hospital
  • Residency: Johns Hopkins Hospital
  • Fellowship: Johns Hopkins Hospital

About Mark Frattini

Biography - Dr. Mark G. Frattini

Dr. Mark G. Frattini is an Associate Professor of Medicine and Director of Research for the Hematologic Malignancies Section in the Hematology/Oncology Division at the Columbia University Medical Center. Previously, Dr. Frattini was a member of the Leukemia Service and Experimental Therapeutics Center at Memorial Sloan-Kettering for almost 11 years. He is a medical oncologist who specializes in the treatment of adult patients with acute and chronic leukemias, myelodisplastic syndromes, and myeloproliferative disorders.

Dr. Frattini's laboratory research focuses on new drug development for acute and chronic leukemias with a special interest in small molecule inhibitors of cell cycle regulated kinases as therapeutic targets. He has discovered a small molecule inhibitor of the cdc7 kinase that is currently in clinical development with a plan for Phase I clinical studies for patients with relapsed and/or chemotherapy-refractory leukemia in 2013. In addition, Dr. Frattini's research involves the development of methods to more precisely determine patient-specific response to various chemotherapeutic agents with a plan to translate this technology into the clinical setting and provide a more personalized approach to therapy for patients with these malignant diseases.

Dr. Frattini has lectured at national and international meetings and has published in various scientific journals, including Blood, Cell, EMBO, JNCCN, Journal of Biological Chemistry, Science, and Proceedings of the National Academy Sciences USA. He received his MD. and PhD in Biochemistry and Molecular Biology from The University of Chicage and completed his fellowship training in medical oncology at The Johns Hopkins Hospital.

Academic Titles

  • Associate Professor of Medicine at CUMC

Committee/Societies/Council Memberships

07/2002 - Present       American Association for Cancer Research Member

07/2002 - Present       American Society of Clinical Oncology Member

07/2002 - Present       American Society of Hematology Member

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Indemnity
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Access (Exchange)
  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Indemnity
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Medicare

  • Traditional Medicare (NY)

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

POMCO

  • POMCO

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO
  • The Empire Plan (NYSHIP)

VNSNY CHOICE

  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
Garden Level
New York, New York 10032
Phone: (212) 305-5098
Fax:
(212) 305-8112
Primary

Research

Grants

A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF VENETOCLAX IN COMBINATION WITH AZACITIDINE VERSUS AZACITIDINE IN TREATMENT NAIVE ELDERLY SUBJECTS WITH ACUTE MYELOID LEUKEMIA WHO ARE INELIGIBLE FOR STANDARD INDUCTION THERAPY (P&S Industry Clinical Trial)

Apr 18 2017 - Apr 18 2022

A PHASE 1B STUDY EVALUATING THE SAFETY, PHARMACOKINETICS AND EFFICACY OF VENETOCLAX AS A SINGLE-AGENT AND IN COMBINATION WITH AZACITIDINE IN SUBJECTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES AFTER HYPOMETHYLATING AGENT-FAILURE (P&S Industry Clinical Trial)

Mar 30 2017 - Mar 30 2022

A RANDOMIZED PHASE 2 STUDY EVALUATING THE SAFETY, PHARMACOKINETICS AND EFFICACY OF VENETOCLAX IN COMBINATION WITH AZACITIDINE COMPARED WITH AZACITIDINE ALONE IN SUBJECTS WITH TREATMENT-NAIVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) (P&S Industry Clinical Trial)

Mar 21 2017 - Mar 21 2022

AN OPEN LABEL, PHASE 1, DOSE ESCALATION STUDY TO CHARACTERIZE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND MAXIMUM TOLERATED DOSE OF BAY 1143572 GIVEN IN A ONCE DAILY OR INTERMITTANT DOSING SCHEDULE IN SUBJECTS WITH ADVANCED ACUTE LEUKEMIA (P&S Industry Clinical Trial)

Feb 26 2015 - Feb 26 2020

A PHASE 1B STUDY OF ABT-199 (GDC-0199) IN COMBINATION WITH AZACITIDINE OR DECITABINE IN TREATMENT NAIVE SUBJECTS WITH ACUTE MYELOGENOUS LEUKEMIA WHO ARE = 65 YEARS OF AGE AND WHO ARE NOT ELIGIBLE FOR STANDARD INDUCTION THERAPY (P&S Industry Clinical Trial)

Dec 19 2014 - Dec 19 2019

CANCER CENTER SUPPORT GRANT (Federal Gov)

Jul 1 2014 - Jun 30 2019

A PHASE 1 STUDY OF SERTRALINE (ZOLOFT) IN COMBINATION WITH TIMED-SEQUENTIAL CYTOSINE ARABINOSIDE (ARA-C) IN ADULTS WITH RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (AML). (Private)

Oct 1 2014 - Sep 30 2017

A RANDOMIZED PHASE II STUDY OF EPIGENETIC PRIMING USING DECITABINE WITH INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) (Federal Gov)

Jun 21 2013 - Jul 31 2013

GENOME-WIDE IDENTIFICATION OF DNA METHYLATION BIOMARKERS IN AML (Federal Gov)

Jan 1 2013 - Jul 31 2013